Interestingly, the study by Corbin et al. shows that KIT inhibition is indeed necessary in addition to inhibition of BCR-ABL1 for maximal suppression of mature CML progenitor cells (CD34+/CD38+). The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.